戴维医疗
(300314)
| 流通市值：20.13亿 | | | 总市值：30.61亿 |
| 流通股本：1.89亿 | | | 总股本：2.88亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 456,258,061.24 | 571,365,961.98 | 502,542,470.16 | 454,691,437.95 |
| 结算备付金 | - | 0 | - | - |
| 拆出资金 | - | 0 | - | - |
| 衍生金融资产 | - | 0 | - | - |
| 应收票据及应收账款 | 47,493,541.24 | 23,824,645.62 | 36,846,625.16 | 26,536,359.67 |
| 其中：应收票据 | - | 0 | 2,600,000 | 2,100,000 |
| 应收账款 | 47,493,541.24 | 23,824,645.62 | 34,246,625.16 | 24,436,359.67 |
| 应收款项融资 | - | 0 | - | - |
| 预付款项 | 26,205,071.44 | 13,623,422.44 | 20,274,010.18 | 19,069,982.48 |
| 应收保费 | - | 0 | - | - |
| 应收分保账款 | - | 0 | - | - |
| 应收分保合同准备金 | - | 0 | - | - |
| 其他应收款合计 | 2,203,402.38 | 3,253,036.41 | 3,040,762.68 | 2,244,283.77 |
| 买入返售金融资产 | - | 0 | - | - |
| 存货 | 161,620,165.81 | 159,373,280.03 | 154,295,514.76 | 150,713,529.97 |
| 合同资产 | - | 0 | - | - |
| 一年内到期的非流动资产 | - | 0 | - | - |
| 其他流动资产 | 589,139.95 | 700,403.96 | 770,008.93 | 1,199,956.72 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 964,633,245.08 | 992,404,613.46 | 977,769,391.87 | 944,455,550.56 |
| 非流动资产: | | | | |
| 发放委托贷款及垫款 | - | 0 | - | - |
| 债权投资 | - | 0 | - | - |
| 其他债权投资 | - | 0 | - | - |
| 长期应收款 | - | 0 | - | - |
| 长期股权投资 | 64,993,234.38 | 48,117,829.23 | 49,192,938.55 | 50,505,814.07 |
| 其他权益工具投资 | - | 0 | - | - |
| 其他非流动金融资产 | 10,000,000 | 10,000,000 | 10,000,000 | 10,000,000 |
| 投资性房地产 | 25,542,989.17 | 26,304,313.06 | 27,065,636.95 | 27,826,960.84 |
| 固定资产 | 150,035,184.27 | 153,864,809.96 | 156,520,260.57 | 156,529,080.08 |
| 在建工程 | 62,001,798.61 | 53,953,308.69 | 27,286,024.28 | 18,348,515.95 |
| 生产性生物资产 | - | 0 | - | - |
| 油气资产 | - | 0 | - | - |
| 使用权资产 | 12,621,795.76 | 13,506,757.99 | 13,560,459.25 | 14,413,351.12 |
| 无形资产 | 46,235,954.93 | 46,599,854.89 | 46,819,105.11 | 46,913,682.11 |
| 开发支出 | - | 0 | - | - |
| 商誉 | 524,103.32 | 524,103.32 | 2,051,541.06 | 2,051,541.06 |
| 长期待摊费用 | 7,673,575.54 | 8,133,990.07 | - | - |
| 递延所得税资产 | 688,268.81 | 658,817.71 | 3,501,651.61 | 3,599,211.21 |
| 其他非流动资产 | 20,014,520.55 | 20,014,520.55 | - | - |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 400,331,425.34 | 381,678,305.47 | 335,997,617.38 | 330,188,156.44 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 1,364,964,670.42 | 1,374,082,918.93 | 1,313,767,009.25 | 1,274,643,707 |
| 流动负债: | | | | |
| 短期借款 | - | 0 | - | - |
| 向中央银行借款 | - | 0 | - | - |
| 吸收存款及同业存放 | - | 0 | - | - |
| 拆入资金 | - | 0 | - | - |
| 交易性金融负债 | - | 0 | - | - |
| 衍生金融负债 | - | 0 | - | - |
| 应付票据及应付账款 | 99,484,516.41 | 119,209,647.28 | 92,690,021.8 | 85,022,167.07 |
| 其中：应付票据 | - | 0 | - | - |
| 应付账款 | 99,484,516.41 | 119,209,647.28 | 92,690,021.8 | 85,022,167.07 |
| 预收款项 | 1,020,335.64 | 1,233,144.32 | 984,073 | 1,008,064.54 |
| 合同负债 | 15,100,097.31 | 17,849,844.46 | 21,362,208.71 | 22,563,522.45 |
| 卖出回购金融资产款 | - | 0 | - | - |
| 应付手续费及佣金 | - | 0 | - | - |
| 应付职工薪酬 | 14,202,584.14 | 36,414,035.61 | 23,104,446.56 | 21,063,682.66 |
| 应交税费 | 8,168,640.29 | 7,940,695.89 | 7,476,000.83 | 6,805,156.36 |
| 其他应付款合计 | 8,406,559.35 | 8,619,950.02 | 7,519,476.63 | 7,043,563.8 |
| 应付分保账款 | - | 0 | - | - |
| 保险合同准备金 | - | 0 | - | - |
| 代理买卖证券款 | - | 0 | - | - |
| 代理承销证券款 | - | 0 | - | - |
| 一年内到期的非流动负债 | 3,162,571.45 | 4,707,094.06 | 2,953,430.58 | 2,902,217.88 |
| 其他流动负债 | 703,093.66 | 1,462,130.5 | 1,415,537.17 | 1,618,707.28 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 150,248,398.25 | 197,436,542.14 | 157,505,195.28 | 148,027,082.04 |
| 非流动负债: | | | | |
| 长期借款 | - | 0 | - | - |
| 应付债券 | - | 0 | - | - |
| 优先股 | - | 0 | - | - |
| 永续债 | - | 0 | - | - |
| 租赁负债 | 9,076,760.72 | 8,978,603.49 | 10,291,783.41 | 10,199,672.26 |
| 长期应付款 | - | 0 | - | - |
| 长期应付职工薪酬 | - | 0 | - | - |
| 预计负债 | - | 0 | - | - |
| 递延收益 | 4,195,361.37 | 4,195,361.37 | 4,459,576.18 | 5,773,790.99 |
| 递延所得税负债 | - | 0 | 2,853,642.91 | 3,004,862.09 |
| 其他非流动负债 | - | 0 | - | - |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 13,272,122.09 | 13,173,964.86 | 17,605,002.5 | 18,978,325.34 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 163,520,520.34 | 210,610,507 | 175,110,197.78 | 167,005,407.38 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 288,000,000 | 288,000,000 | 288,000,000 | 288,000,000 |
| 其他权益工具 | - | 0 | - | - |
| 优先股 | - | 0 | - | - |
| 永续债 | - | 0 | - | - |
| 资本公积 | 175,534,430.38 | 175,534,430.38 | 175,534,430.38 | 175,534,430.38 |
| 减:库存股 | - | 0 | - | - |
| 其他综合收益 | -135,490.61 | 0 | - | - |
| 专项储备 | - | 0 | - | - |
| 盈余公积 | 86,831,291.28 | 86,831,291.28 | 78,216,698.96 | 78,216,698.96 |
| 一般风险准备 | - | 0 | - | - |
| 未分配利润 | 651,213,919.03 | 613,106,690.27 | 596,905,682.13 | 565,887,170.28 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 1,201,444,150.08 | 1,163,472,411.93 | 1,138,656,811.47 | 1,107,638,299.62 |
| 少数股东权益 | - | 0 | - | - |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 1,201,444,150.08 | 1,163,472,411.93 | 1,138,656,811.47 | 1,107,638,299.62 |
| 负债和股东权益合计 | 1,364,964,670.42 | 1,374,082,918.93 | 1,313,767,009.25 | 1,274,643,707 |
| 公告日期 | 2024-04-20 | 2024-04-09 | 2023-10-25 | 2023-08-22 |
| 审计意见(境内) | | 标准无保留意见 | | |